These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23121445)

  • 1. Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo.
    Stenton GR; Mackenzie LF; Tam P; Cross JL; Harwig C; Raymond J; Toews J; Wu J; Ogden N; MacRury T; Szabo C
    Br J Pharmacol; 2013 Mar; 168(6):1506-18. PubMed ID: 23121445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo.
    Stenton GR; Mackenzie LF; Tam P; Cross JL; Harwig C; Raymond J; Toews J; Chernoff D; MacRury T; Szabo C
    Br J Pharmacol; 2013 Mar; 168(6):1519-29. PubMed ID: 23121409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma.
    Leaker BR; Barnes PJ; O'Connor BJ; Ali FY; Tam P; Neville J; Mackenzie LF; MacRury T
    Clin Exp Allergy; 2014 Sep; 44(9):1146-53. PubMed ID: 25040039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.
    Lemm EA; Valle-Argos B; Smith LD; Richter J; Gebreselassie Y; Carter MJ; Karolova J; Svaton M; Helman K; Weston-Bell NJ; Karydis L; Williamson CT; Lenz G; Pettigrew J; Harwig C; Stevenson FK; Cragg M; Forconi F; Steele AJ; Cross J; Mackenzie L; Klener P; Packham G
    Clin Cancer Res; 2020 Apr; 26(7):1700-1711. PubMed ID: 31831562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AQX-1125, small molecule SHIP1 activator inhibits bleomycin-induced pulmonary fibrosis.
    Cross J; Stenton GR; Harwig C; Szabo C; Genovese T; Di Paola R; Esposito E; Cuzzocrea S; Mackenzie LF
    Br J Pharmacol; 2017 Sep; 174(18):3045-3057. PubMed ID: 28658529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.
    Ong CJ; Ming-Lum A; Nodwell M; Ghanipour A; Yang L; Williams DE; Kim J; Demirjian L; Qasimi P; Ruschmann J; Cao LP; Ma K; Chung SW; Duronio V; Andersen RJ; Krystal G; Mui AL
    Blood; 2007 Sep; 110(6):1942-9. PubMed ID: 17502453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoinositide lipid phosphatase SHIP1 and PTEN coordinate to regulate cell migration and adhesion.
    Mondal S; Subramanian KK; Sakai J; Bajrami B; Luo HR
    Mol Biol Cell; 2012 Apr; 23(7):1219-30. PubMed ID: 22323291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A key role for the phosphorylation of Ser440 by the cyclic AMP-dependent protein kinase in regulating the activity of the Src homology 2 domain-containing Inositol 5'-phosphatase (SHIP1).
    Zhang J; Ravichandran KS; Garrison JC
    J Biol Chem; 2010 Nov; 285(45):34839-49. PubMed ID: 20810657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of the Src homology 2 domain-containing inositol 5'-phosphatase (SHIP1) by the cyclic AMP-dependent protein kinase.
    Zhang J; Walk SF; Ravichandran KS; Garrison JC
    J Biol Chem; 2009 Jul; 284(30):20070-8. PubMed ID: 19494109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-T cell activation linker promotes mast cell survival by dampening the recruitment of SHIP1 by linker for activation of T cells.
    Roget K; Malissen M; Malbec O; Malissen B; Daëron M
    J Immunol; 2008 Mar; 180(6):3689-98. PubMed ID: 18322174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of cell polarity and motility by the PtdIns(3,4,5)P3 phosphatase SHIP1.
    Nishio M; Watanabe K; Sasaki J; Taya C; Takasuga S; Iizuka R; Balla T; Yamazaki M; Watanabe H; Itoh R; Kuroda S; Horie Y; Förster I; Mak TW; Yonekawa H; Penninger JM; Kanaho Y; Suzuki A; Sasaki T
    Nat Cell Biol; 2007 Jan; 9(1):36-44. PubMed ID: 17173042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophages from 11beta-hydroxysteroid dehydrogenase type 1-deficient mice exhibit an increased sensitivity to lipopolysaccharide stimulation due to TGF-beta-mediated up-regulation of SHIP1 expression.
    Zhang TY; Daynes RA
    J Immunol; 2007 Nov; 179(9):6325-35. PubMed ID: 17947710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic studies on the indane SHIP1 agonist AQX-1125.
    Dungan OM; Dormann S; Fernandes S; Duffy BC; Effiong DG; Kerr WG; Chisholm JD
    Org Biomol Chem; 2022 May; 20(19):4016-4020. PubMed ID: 35506893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SHIP1 is a repressor of mast cell hyperplasia, cytokine production, and allergic inflammation in vivo.
    Haddon DJ; Antignano F; Hughes MR; Blanchet MR; Zbytnuik L; Krystal G; McNagny KM
    J Immunol; 2009 Jul; 183(1):228-36. PubMed ID: 19542434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain Syndrome.
    Nickel JC; Egerdie B; Davis E; Evans R; Mackenzie L; Shrewsbury SB
    J Urol; 2016 Sep; 196(3):747-54. PubMed ID: 26968644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism.
    An H; Xu H; Zhang M; Zhou J; Feng T; Qian C; Qi R; Cao X
    Blood; 2005 Jun; 105(12):4685-92. PubMed ID: 15701712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms controlling membrane recruitment and activation of the autoinhibited SHIP1 inositol 5-phosphatase.
    Waddell GL; Drew EE; Rupp HP; Hansen SD
    J Biol Chem; 2023 Aug; 299(8):105022. PubMed ID: 37423304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases.
    Mertsching E; Bafetti L; Hess H; Perper S; Giza K; Allen LC; Negrou E; Hathaway K; Hopp J; Chung J; Perret D; Shields M; Saxon A; Kehry MR
    J Allergy Clin Immunol; 2008 Feb; 121(2):441-447.e5. PubMed ID: 17949802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SHIP1 regulates MSC numbers and their osteolineage commitment by limiting induction of the PI3K/Akt/β-catenin/Id2 axis.
    Iyer S; Viernes DR; Chisholm JD; Margulies BS; Kerr WG
    Stem Cells Dev; 2014 Oct; 23(19):2336-51. PubMed ID: 24857423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SH2 inositol 5-phosphatase Ship1 is recruited in an SH2-dependent manner to the erythropoietin receptor.
    Mason JM; Beattie BK; Liu Q; Dumont DJ; Barber DL
    J Biol Chem; 2000 Feb; 275(6):4398-406. PubMed ID: 10660611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.